|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Memorial Hospital of Rhode Island Ortho-McNeil Neurologics, Inc. |
|---|---|
| Information provided by: | Memorial Hospital of Rhode Island |
| ClinicalTrials.gov Identifier: | NCT00211588 |
Purpose
The aim of the study is to determine whether galantamine stabilizes or improves thinking abilities in individuals with Parkinson's disease. Individuals included in the study have minor complaints about thinking such as problems with concentration or memory but do not have dementia. This medication has been shown to have a positive effect on stabilizing memory in individuals with Alzheimer's disease. It is FDA approved for use in elderly individuals with Alzheimer's disease. It is hypothesized that galantamine will stabilize or improve executive and attentional functions in individuals with Parkinson's.
| Condition | Intervention |
|---|---|
|
Parkinson's Disease |
Drug: galantamine |
| Study Type: | Interventional |
| Study Design: | Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Investigator Initiated Study: Galantamine CR Potential Enhancement of Attentional and Executive Function in Non-Demented Patients With Parkinson's Disease |
| Estimated Enrollment: | 90 |
| Study Start Date: | June 2004 |
| Estimated Study Completion Date: | May 2007 |
While several cholinesterase inhibitors have effectiveness in Alzheimer's disease (AD), galantamine is unique since it has a dual mode of action: inhibition of acetylcholinesterase and modulation of nicotinic acetylcholine receptors.As Parkinson's disease (PD) impacts frontal systems, executive cognition rather than memory function (mediated by medial temporal) would be the targeted area for potential improvement. This single center, double blind, placebo controlled study compares a group of PD patients treated with galantamine to a group of PD patients who are not treated with this medication on a series of cognitive tasks that examine attention and executive control.
Eligibility| Ages Eligible for Study: | 60 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Rhode Island | |
| Memorial Hospital of RI | |
| Pawtucket, Rhode Island, United States, 02860 | |
| Principal Investigator: | Joseph H Friedman, M.D. | NeuroHealth |
| Study Director: | Janet Grace, Ph.D. | Memorial Hospital of RI |
More Information
| Study ID Numbers: | GAL-EMR-4022 |
| Study First Received: | September 13, 2005 |
| Last Updated: | May 4, 2007 |
| ClinicalTrials.gov Identifier: | NCT00211588 |
| Health Authority: | United States: Food and Drug Administration |
|
cognition |
|
Ganglion Cysts Galantamine Movement Disorders Parkinson Disease Basal Ganglia Diseases |
Central Nervous System Diseases Parkinsonian Disorders Neurodegenerative Diseases Brain Diseases |
|
Parasympathomimetics Nootropic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Nervous System Diseases Physiological Effects of Drugs Enzyme Inhibitors |
Cholinergic Agents Pharmacologic Actions Cholinesterase Inhibitors Autonomic Agents Therapeutic Uses Peripheral Nervous System Agents Central Nervous System Agents |
